{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T12:53:52Z","timestamp":1794920032706,"version":"4.9.1"},"reference-count":152,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s00467-026-07180-2","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T12:25:49Z","timestamp":1771849549000},"page":"2799-2823","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Infection prophylaxis following anti-CD20 monoclonal antibodies in childhood kidney diseases"],"prefix":"10.1007","volume":"41","author":[{"given":"Dongyang","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona Fung-Yee","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua Sung-Chih","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1463-6005","authenticated-orcid":false,"given":"Eugene Yu-Hin","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4242-3154","authenticated-orcid":false,"given":"Alison Lap-Tak","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,23]]},"reference":[{"key":"7180_CR1","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1038\/s41573-020-00092-2","volume":"20","author":"DSW Lee","year":"2021","unstructured":"Lee DSW, Rojas OL, Gommerman JL (2021) B cell depletion therapies in autoimmune disease: advances and mechanistic insights. Nat Rev Drug Discov 20:179\u2013199. https:\/\/doi.org\/10.1038\/s41573-020-00092-2","journal-title":"Nat Rev Drug Discov"},{"key":"7180_CR2","doi-asserted-by":"publisher","first-page":"803","DOI":"10.2165\/00003495-200363080-00005","volume":"63","author":"GL Plosker","year":"2003","unstructured":"Plosker GL, Figgitt DP (2003) Rituximab: a review of its use in non-Hodgkin\u2019s lymphoma and chronic lymphocytic leukaemia. Drugs 63:803\u2013843. https:\/\/doi.org\/10.2165\/00003495-200363080-00005","journal-title":"Drugs"},{"key":"7180_CR3","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.biopha.2004.04.006","volume":"58","author":"L Virgolini","year":"2004","unstructured":"Virgolini L, Marzocchi V (2004) Rituximab in autoimmune diseases. Biomed Pharmacother 58:299\u2013309. https:\/\/doi.org\/10.1016\/j.biopha.2004.04.006","journal-title":"Biomed Pharmacother"},{"key":"7180_CR4","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1053\/j.ajkd.2022.05.013","volume":"81","author":"M Marlais","year":"2023","unstructured":"Marlais M, Wlodkowski T, Printza N, Kronsteiner D, Krisam R, Sauer L, Aksenova M, Ashoor I, Awan A, Bacchetta J, Balasubramanian R, Basu B, Bekassy Z, Boyer O, Chan EY, Csaicsich D, Decramer S, Dorresteijn E, Drozynska-Duklas M, Eid LA, Espinosa L, Ferraris V, Flogelova H, Forero-Delgadillo J, Gianviti A, Gracchi V, Gonzalez ML, Hansen M, Hattori M, Hong X, Hooman N, Ivanov D, Kang HG, Karava V, Kazyra I, Lungu A, Marks S, Maxted A, Moczulska A, Muller R, Nastausheva T, Parolin M, Pecoraro C, Principi I, Sanchez-Kazi C, Saygili S, Schild R, Shenoy M, Sinha R, Spizzirri AP, Stack M, Szczepanska M, Tsygin A, Tzeng J, Urbonas V, Zapata C, Zieg J, Schaefer F, Vivarelli M, Tullus K (2023) Clinical factors and adverse kidney outcomes in children with antineutrophil cytoplasmic antibody-associated glomerulonephritis. Am J Kidney Dis 81:119\u2013122. https:\/\/doi.org\/10.1053\/j.ajkd.2022.05.013","journal-title":"Am J Kidney Dis"},{"key":"7180_CR5","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1681\/ASN.2013030251","volume":"25","author":"P Ruggenenti","year":"2014","unstructured":"Ruggenenti P, Ruggiero B, Cravedi P, Vivarelli M, Massella L, Maras\u00e0 M, Chianca A, Rubis N, Ene-Iordache B, Rudnicki M, Pollastro RM, Capasso G, Pisani A, Pennesi M, Emma F, Remuzzi G (2014) Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome. J Am Soc Nephrol 25:850\u2013863. https:\/\/doi.org\/10.1681\/ASN.2013030251","journal-title":"J Am Soc Nephrol"},{"key":"7180_CR6","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1007\/s00467-004-1434-z","volume":"19","author":"K Benz","year":"2004","unstructured":"Benz K, D\u00f6tsch J, Rascher W, Stachel D (2004) Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy. Pediatr Nephrol 19:794\u2013797. https:\/\/doi.org\/10.1007\/s00467-004-1434-z","journal-title":"Pediatr Nephrol"},{"key":"7180_CR7","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/S0140-6736(14)60541-9","volume":"384","author":"K Iijima","year":"2014","unstructured":"Iijima K, Sako M, Nozu K, Mori R, Tuchida N, Kamei K, Miura K, Aya K, Nakanishi K, Ohtomo Y, Takahashi S, Tanaka R, Kaito H, Nakamura H, Ishikura K, Ito S, Ohashi Y, Rituximab for Childhood-onset Refractory Nephrotic Syndrome (RCRNS) Study Group (2014) Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet 384:1273\u20131281. https:\/\/doi.org\/10.1016\/S0140-6736(14)60541-9","journal-title":"Lancet"},{"key":"7180_CR8","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1681\/ASN.2014080799","volume":"26","author":"P Ravani","year":"2015","unstructured":"Ravani P, Rossi R, Bonanni A, Quinn RR, Sica F, Bodria M, Pasini A, Montini G, Edefonti A, Belingheri M, De Giovanni D, Barbano G, Degl\u2019Innocenti L, Scolari F, Murer L, Reiser J, Fornoni A, Ghiggeri GM (2015) Rituximab in children with steroid-dependent nephrotic syndrome: a multicenter, open-label, noninferiority, randomized controlled trial. J Am Soc Nephrol 26:2259\u20132266. https:\/\/doi.org\/10.1681\/ASN.2014080799","journal-title":"J Am Soc Nephrol"},{"key":"7180_CR9","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1007\/s00467-022-05739-3","volume":"38","author":"A Trautmann","year":"2023","unstructured":"Trautmann A, Boyer O, Hodson E, Bagga A, Gipson DS, Samuel S, Wetzels J, Alhasan K, Banerjee S, Bhimma R, Bonilla-Felix M, Cano F, Christian M, Hahn D, Kang HG, Nakanishi K, Safouh H, Trachtman H, Xu H, Cook W, Vivarelli M, Haffner D, International Pediatric Nephrology Association (2023) IPNA clinical practice recommendations for the diagnosis and management of children with steroid-sensitive nephrotic syndrome. Pediatr Nephrol 38:877\u2013919. https:\/\/doi.org\/10.1007\/s00467-022-05739-3","journal-title":"Pediatr Nephrol"},{"key":"7180_CR10","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1007\/s00467-020-04519-1","volume":"35","author":"A Trautmann","year":"2020","unstructured":"Trautmann A, Vivarelli M, Samuel S, Gipson D, Sinha A, Schaefer F, Hui NK, Boyer O, Saleem MA, Feltran L, M\u00fcller-Deile J, Becker JU, Cano F, Xu H, Lim YN, Smoyer W, Anochie I, Nakanishi K, Hodson E, Haffner D, International Pediatric Nephrology Association (2020) IPNA clinical practice recommendations for the diagnosis and management of children with steroid-resistant nephrotic syndrome. Pediatr Nephrol 35:1529\u20131561. https:\/\/doi.org\/10.1007\/s00467-020-04519-1","journal-title":"Pediatr Nephrol"},{"key":"7180_CR11","doi-asserted-by":"publisher","first-page":"S241","DOI":"10.1016\/j.kint.2024.11.007","volume":"107","author":"J Floege","year":"2025","unstructured":"Floege J, Gibson KL, Vivarelli M, Liew A, Radhakrishnan J, Rovin BH (2025) KDIGO 2025 clinical practice guideline for the management of nephrotic syndrome in children. Kidney Int 107:S241\u2013S289. https:\/\/doi.org\/10.1016\/j.kint.2024.11.007","journal-title":"Kidney Int"},{"key":"7180_CR12","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1007\/s00467-024-06634-9","volume":"40","author":"EY Chan","year":"2025","unstructured":"Chan EY, Boyer O (2025) Childhood idiopathic nephrotic syndrome: recent advancements shaping future guidelines. Pediatr Nephrol 40:2431\u20132442. https:\/\/doi.org\/10.1007\/s00467-024-06634-9","journal-title":"Pediatr Nephrol"},{"key":"7180_CR13","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2021.05.021","volume":"100","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group","year":"2021","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group (2021) KDIGO 2021 clinical practice guideline for the management of glomerular diseases. Kidney Int 100:S1\u2013S276. https:\/\/doi.org\/10.1016\/j.kint.2021.05.021","journal-title":"Kidney Int"},{"key":"7180_CR14","doi-asserted-by":"publisher","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group (2009) KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 9(Suppl 3):S1-155. https:\/\/doi.org\/10.1111\/j.1600-6143.2009.02834.x","DOI":"10.1111\/j.1600-6143.2009.02834.x"},{"key":"7180_CR15","doi-asserted-by":"publisher","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) ANCA Vasculitis Work Group (2024) KDIGO 2024 clinical practice guideline for the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis. Kidney Int 105:S71\u2013S116. https:\/\/doi.org\/10.1016\/j.kint.2023.10.008","DOI":"10.1016\/j.kint.2023.10.008"},{"key":"7180_CR16","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2023.09.002","volume":"105","author":"BH Rovin","year":"2024","unstructured":"Rovin BH, Ayoub IM, Chan TM, Liu Z-H, Mej\u00eda-Vilet JM, Floege J (2024) KDIGO 2024 clinical practice guideline for the management of lupus nephritis. Kidney Int 105:S1\u2013S69. https:\/\/doi.org\/10.1016\/j.kint.2023.09.002","journal-title":"Kidney Int"},{"key":"7180_CR17","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1016\/j.kint.2024.09.011","volume":"106","author":"EY Chan","year":"2024","unstructured":"Chan EY, Sinha A, Yu ELM, Akhtar N, Angeletti A, Bagga A, Banerjee S, Boyer O, Chan CY, Francis A, Ghiggeri GM, Hamada R, Hari P, Hooman N, Hopf LS, I MI, Ijaz I, Ivanov DD, Kalra S, Kang HG, Lucchetti L, Lugani F, Ma AL, Morello W, Camargo Muniz MD, Pradhan SK, Prikhodina L, Raafat RH, Sinha R, Teo S, Tomari K, Vivarelli M, Webb H, Yap HK, Yap DY, Tullus K (2024) An international, multi-center study evaluated rituximab therapy in childhood steroid-resistant nephrotic syndrome. Kidney Int 106:1146\u20131157. https:\/\/doi.org\/10.1016\/j.kint.2024.09.011","journal-title":"Kidney Int"},{"key":"7180_CR18","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.kint.2025.05.039","volume":"108","author":"EY Chan","year":"2025","unstructured":"Chan EY, Marks SD (2025) Childhood-onset lupus nephritis: unique aspects and challenges in management. Kidney Int 108:799\u2013810. https:\/\/doi.org\/10.1016\/j.kint.2025.05.039","journal-title":"Kidney Int"},{"key":"7180_CR19","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1007\/s00467-013-2485-9","volume":"28","author":"A-L Sellier-Leclerc","year":"2013","unstructured":"Sellier-Leclerc A-L, Belli E, Gu\u00e9rin V, Dorfm\u00fcller P, Desch\u00eanes G (2013) Fulminant viral myocarditis after rituximab therapy in pediatric nephrotic syndrome. Pediatr Nephrol 28:1875\u20131879. https:\/\/doi.org\/10.1007\/s00467-013-2485-9","journal-title":"Pediatr Nephrol"},{"key":"7180_CR20","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1093\/annonc\/mdq583","volume":"22","author":"AM Evens","year":"2011","unstructured":"Evens AM, Jovanovic BD, Su YC, Raisch DW, Ganger D, Belknap SM, Dai MS, Chiu BC, Fintel B, Cheng Y, Chuang SS, Lee MY, Chen TY, Lin SF, Kuo CY (2011) Rituximab-associated hepatitis B virus (HBV) reactivation in lymphoproliferative diseases: meta-analysis and examination of FDA safety reports. Ann Oncol 22:1170\u20131180. https:\/\/doi.org\/10.1093\/annonc\/mdq58","journal-title":"Ann Oncol"},{"key":"7180_CR21","doi-asserted-by":"publisher","first-page":"e184169","DOI":"10.1001\/jamanetworkopen.2018.4169","volume":"1","author":"S Barmettler","year":"2018","unstructured":"Barmettler S, Ong MS, Farmer JR, Choi H, Walter J (2018) Association of immunoglobulin levels, infectious risk, and mortality with rituximab and hypogammaglobulinemia. JAMA Netw Open 1:e184169. https:\/\/doi.org\/10.1001\/jamanetworkopen.2018.4169","journal-title":"JAMA Netw Open"},{"key":"7180_CR22","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.36321","volume":"4","author":"CL McAtee","year":"2021","unstructured":"McAtee CL, Lubega J, Underbrink K, Curry K, Msaouel P, Barrow M, Muscal E, Lotze T, Srivaths P, Forbes LR, Allen C, Bernhardt MB (2021) Association of rituximab use with adverse events in children, adolescents, and young adults. JAMA Netw Open 4:e2036321. https:\/\/doi.org\/10.1001\/jamanetworkopen.2020.36321","journal-title":"JAMA Netw Open"},{"key":"7180_CR23","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2215\/CJN.08570722","volume":"18","author":"EY Chan","year":"2023","unstructured":"Chan EY, Yap DY, Colucci M, Ma AL, Parekh RS, Tullus K (2023) Use of rituximab in childhood idiopathic nephrotic syndrome. Clin J Am Soc Nephrol 18:533\u2013548. https:\/\/doi.org\/10.2215\/CJN.08570722","journal-title":"Clin J Am Soc Nephrol"},{"key":"7180_CR24","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1007\/s00467-021-05345-9","volume":"37","author":"EY-H Chan","year":"2022","unstructured":"Chan EY-H, Ma AL-T, Tullus K (2022) Hypogammaglobulinaemia following rituximab therapy in childhood nephrotic syndrome. Pediatr Nephrol 37:927\u2013931. https:\/\/doi.org\/10.1007\/s00467-021-05345-9","journal-title":"Pediatr Nephrol"},{"key":"7180_CR25","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1002\/art.41501","volume":"73","author":"R Zonozi","year":"2021","unstructured":"Zonozi R, Wallace ZS, Laliberte K, Huizenga NR, Rosenthal JM, Rhee EP, Cortazar FB, Niles JL (2021) Incidence, clinical features, and outcomes of late-onset neutropenia from rituximab for autoimmune disease. Arthritis Rheum 73:347\u2013354. https:\/\/doi.org\/10.1002\/art.41501","journal-title":"Arthritis Rheum"},{"key":"7180_CR26","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.jaip.2024.12.024","volume":"13","author":"IM Otani","year":"2025","unstructured":"Otani IM, Ballow M (2025) If and when to consider prophylactic immunoglobulin replacement therapy in secondary hypogammaglobulinemia. J Allergy Clin Immunol Pract 13:511\u2013521. https:\/\/doi.org\/10.1016\/j.jaip.2024.12.024","journal-title":"J Allergy Clin Immunol Pract"},{"key":"7180_CR27","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1182\/blood-2002-06-1761","volume":"101","author":"MS Cragg","year":"2003","unstructured":"Cragg MS, Morgan SM, Chan HTC, Morgan BP, Filatov AV, Johnson PWM, French RR, Glennie MJ (2003) Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood 101:1045\u20131052. https:\/\/doi.org\/10.1182\/blood-2002-06-1761","journal-title":"Blood"},{"key":"7180_CR28","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s00467-023-05974-2","volume":"39","author":"FF Lai","year":"2024","unstructured":"Lai FF, Chan EY, Tullus K, Ma AL (2024) Therapeutic drug monitoring in childhood idiopathic nephrotic syndrome: a state of the art review. Pediatr Nephrol 39:85\u2013103. https:\/\/doi.org\/10.1007\/s00467-023-05974-2","journal-title":"Pediatr Nephrol"},{"key":"7180_CR29","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1093\/ndt\/gfaf021","volume":"40","author":"GM Rossi","year":"2025","unstructured":"Rossi GM, Baier E, Vaglio A (2025) Obinutuzumab for the management of immune-mediated glomerular diseases. Nephrol Dial Transplant 40:1443\u20131448. https:\/\/doi.org\/10.1093\/ndt\/gfaf021","journal-title":"Nephrol Dial Transplant"},{"key":"7180_CR30","unstructured":"Genentech, Inc. (2021) Rituxan (rituximab) prescribing information [package insert]. U.S. Food and Drug Administration. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/103705s5467lbl.pdf. Accessed 13 Aug 2025"},{"key":"7180_CR31","doi-asserted-by":"publisher","unstructured":"Chan EYH, Lin KYK, Yap DYH, Ma ALT (2025) Obinutuzumab as a viable therapeutic strategy in rituximab-refractory childhood frequently relapsing, steroid-dependent nephrotic syndrome that relapsed during B-cell depletion. Pediatr Nephrol 40:711\u2013714. https:\/\/doi.org\/10.1007\/s00467-024-06570-8","DOI":"10.1007\/s00467-024-06570-8"},{"key":"7180_CR32","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1681\/ASN.2021111472","volume":"33","author":"EY Chan","year":"2022","unstructured":"Chan EY, Yu ELM, Angeletti A, Arslan Z, Basu B, Boyer O, Chan CY, Colucci M, Dorval G, Dossier C, Drovandi S, Ghiggeri GM, Gipson DS, Hamada R, Hogan J, Ishikura K, Kamei K, Kemper MJ, Ma AL, Parekh RS, Radhakrishnan S, Saini P, Shen Q, Sinha R, Subun C, Teo S, Vivarelli M, Webb H, Xu H, Yap HK, Tullus K (2022) Long-term efficacy and safety of repeated rituximab to maintain remission in idiopathic childhood nephrotic syndrome: an international study. J Am Soc Nephrol 33:1193\u20131207. https:\/\/doi.org\/10.1681\/ASN.2021111472","journal-title":"J Am Soc Nephrol"},{"key":"7180_CR33","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1093\/ckj\/sfw101","volume":"10","author":"C Trivin","year":"2017","unstructured":"Trivin C, Tran A, Moulin B, Choukroun G, Gatault P, Courivaud C, Augusto JF, Ficheux M, Vigneau C, Thervet E, Karras A (2017) Infectious complications of a rituximab-based immunosuppressive regimen in patients with glomerular disease. Clin Kidney J 10:461\u2013469. https:\/\/doi.org\/10.1093\/ckj\/sfw101","journal-title":"Clin Kidney J"},{"key":"7180_CR34","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1093\/ckj\/sfx038","volume":"10","author":"A Nixon","year":"2017","unstructured":"Nixon A, Ogden L, Woywodt A, Dhaygude A (2017) Infectious complications of rituximab therapy in renal disease. Clin Kidney J 10:455\u2013460. https:\/\/doi.org\/10.1093\/ckj\/sfx038","journal-title":"Clin Kidney J"},{"key":"7180_CR35","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s10067-014-2509-2","volume":"33","author":"M Heusele","year":"2014","unstructured":"Heusele M, Clerson P, Guery B, Lambert M, Launay D, Lefevre G, Morell-Dubois S, Maillard H, Le Gouellec N, Hatron PY, Hachulla E (2014) Risk factors for severe bacterial infections in patients with systemic autoimmune diseases receiving rituximab. Clin Rheumatol 33:799\u2013805. https:\/\/doi.org\/10.1007\/s10067-014-2509-2","journal-title":"Clin Rheumatol"},{"key":"7180_CR36","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s00467-012-2286-6","volume":"28","author":"M Sato","year":"2013","unstructured":"Sato M, Ito S, Ogura M, Kamei K, Miyairi I, Miyata I, Higuchi M, Matsuoka K (2013) Atypical Pneumocystis jiroveci pneumonia with multiple nodular granulomas after rituximab for refractory nephrotic syndrome. Pediatr Nephrol 28:145\u2013149. https:\/\/doi.org\/10.1007\/s00467-012-2286-6","journal-title":"Pediatr Nephrol"},{"key":"7180_CR37","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/hep.27716","volume":"62","author":"M Barone","year":"2015","unstructured":"Barone M, Notarnicola A, Lopalco G, Viggiani MT, Sebastiani F, Covelli M, Iannone F, Avolio AW, Di Leo A, Cantarini L, Lapadula G (2015) Safety of long-term biologic therapy in rheumatologic patients with a previously resolved hepatitis B viral infection. Hepatology 62:40\u201346. https:\/\/doi.org\/10.1002\/hep.27716","journal-title":"Hepatology"},{"key":"7180_CR38","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jcv.2018.11.010","volume":"110","author":"I Los-Arcos","year":"2019","unstructured":"Los-Arcos I, Len O, Perello M, Torres IB, Codina G, Esperalba J, Sellar\u00e9s J, Moreso F, Seron D, Gavald\u00e0 J (2019) Is antibody-mediated rejection in kidney transplant recipients a risk factor for developing cytomegalovirus or BK virus infection? Results from a case-control study. J Clin Virol 110:45\u201350. https:\/\/doi.org\/10.1016\/j.jcv.2018.11.010","journal-title":"J Clin Virol"},{"key":"7180_CR39","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1111\/tri.13613","volume":"33","author":"E Bailly","year":"2020","unstructured":"Bailly E, Ville S, Blancho G, Morelon E, Bamoulid J, Caillard S, Chatelet V, Malvezzi P, Tourret J, Vuiblet V, Anglicheau D, Bertrand D, Grimbert P, Haidar F, Hazzan M, Kamar N, Merville P, Mousson C, Pernin V, Pouteil-Noble C, Purgus R, Sayegh J, Westeel P-F, Sautenet B, Gatault P, B\u00fcchler M (2020) An extension of the RITUX-ERAH study, multicenter randomized clinical trial comparing rituximab to placebo in acute antibody-mediated rejection after renal transplantation. Transpl Int 33:786\u2013795. https:\/\/doi.org\/10.1111\/tri.13613","journal-title":"Transpl Int"},{"key":"7180_CR40","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1002\/jca.21897","volume":"36","author":"H Naciri Bennani","year":"2021","unstructured":"Naciri Bennani H, Daligault M, Noble J, Bardy B, Motte L, Giovannini D, Emprou C, Fiard G, Imerzoukene F, Bourdin A, Masson D, Janbon B, Malvezzi P, Rostaing L, Jouve T (2021) Treatment of antibody-mediated rejection with double-filtration plasmapheresis, low dose IVIg plus rituximab after kidney transplantation. J Clin Apher 36:584\u2013594. https:\/\/doi.org\/10.1002\/jca.21897","journal-title":"J Clin Apher"},{"key":"7180_CR41","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s13365-018-0615-7","volume":"24","author":"JR Berger","year":"2018","unstructured":"Berger JR, Malik V, Lacey S, Brunetta P, Lehane PB (2018) Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: a rare event. J Neurovirol 24:323\u2013331. https:\/\/doi.org\/10.1007\/s13365-018-0615-7","journal-title":"J Neurovirol"},{"key":"7180_CR42","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.2215\/CJN.0000000000000288","volume":"18","author":"C Dossier","year":"2023","unstructured":"Dossier C, Bonneric S, Baudouin V, Kwon T, Prim B, Cambier A, Couderc A, Moreau C, Deschenes G, Hogan J (2023) Obinutuzumab in frequently relapsing and steroid-dependent nephrotic syndrome in children. Clin J Am Soc Nephrol 18:1555\u20131562. https:\/\/doi.org\/10.2215\/CJN.0000000000000288","journal-title":"Clin J Am Soc Nephrol"},{"key":"7180_CR43","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/art.41901","volume":"74","author":"P Brogan","year":"2022","unstructured":"Brogan P, Yeung RSM, Cleary G, Rangaraj S, Kasapcopur O, Hersh AO, Li S, Paripovic D, Schikler K, Zeft A, Bracaglia C, Eleftheriou D, Pordeli P, Melega S, Jamois C, Gaudreault J, Michalska M, Brunetta P, Cooper JC, Lehane PB (2022) Phase IIa global study evaluating rituximab for the treatment of pediatric patients with granulomatosis with polyangiitis or microscopic polyangiitis. Arthritis Rheum 74:124\u2013133. https:\/\/doi.org\/10.1002\/art.41901","journal-title":"Arthritis Rheum"},{"key":"7180_CR44","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1007\/s00467-008-0814-1","volume":"23","author":"V Guigonis","year":"2008","unstructured":"Guigonis V, Dallocchio A, Baudouin V, Dehennault M, Hachon-Le Camus C, Afanetti M, Groothoff J, Llanas B, Niaudet P, Nivet H, Raynaud N, Taque S, Ronco P, Bouissou F (2008) Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases. Pediatr Nephrol 23:1269\u20131279. https:\/\/doi.org\/10.1007\/s00467-008-0814-1","journal-title":"Pediatr Nephrol"},{"key":"7180_CR45","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1007\/s00467-009-1191-0","volume":"24","author":"K Kamei","year":"2009","unstructured":"Kamei K, Ito S, Nozu K, Fujinaga S, Nakayama M, Sako M, Saito M, Yoneko M, Iijima K (2009) Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children. Pediatr Nephrol 24:1321\u20131328. https:\/\/doi.org\/10.1007\/s00467-009-1191-0","journal-title":"Pediatr Nephrol"},{"key":"7180_CR46","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.2215\/CJN.09421010","volume":"6","author":"P Ravani","year":"2011","unstructured":"Ravani P, Magnasco A, Edefonti A, Murer L, Rossi R, Ghio L, Benetti E, Scozzola F, Pasini A, Dallera N, Sica F, Belingheri M, Scolari F, Ghiggeri GM (2011) Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial. Clin J Am Soc Nephrol 6:1308\u20131315. https:\/\/doi.org\/10.2215\/CJN.09421010","journal-title":"Clin J Am Soc Nephrol"},{"key":"7180_CR47","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1681\/ASN.2011080775","volume":"23","author":"A Magnasco","year":"2012","unstructured":"Magnasco A, Ravani P, Edefonti A, Murer L, Ghio L, Belingheri M, Benetti E, Murtas C, Messina G, Massella L, Porcellini MG, Montagna M, Regazzi M, Scolari F, Ghiggeri GM (2012) Rituximab in children with resistant idiopathic nephrotic syndrome. Clin J Am Soc Nephrol 23:1117\u20131124. https:\/\/doi.org\/10.1681\/ASN.2011080775","journal-title":"Clin J Am Soc Nephrol"},{"key":"7180_CR48","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/ki.2013.211","volume":"84","author":"P Ravani","year":"2013","unstructured":"Ravani P, Ponticelli A, Siciliano C, Fornoni A, Magnasco A, Sica F, Bodria M, Caridi G, Wei C, Belingheri M, Ghio L, Merscher-Gomez S, Edefonti A, Pasini A, Montini G, Murtas C, Wang X, Muruve D, Vaglio A, Martorana D, Pani A, Scolari F, Reiser J, Ghiggeri GM (2013) Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome. Kidney Int 84:1025\u20131033. https:\/\/doi.org\/10.1038\/ki.2013.211","journal-title":"Kidney Int"},{"key":"7180_CR49","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s12519-014-0453-5","volume":"10","author":"L Sun","year":"2014","unstructured":"Sun L, Xu H, Shen Q, Cao Q, Rao J, Liu H-M, Fang X-Y, Zhou L-J (2014) Efficacy of rituximab therapy in children with refractory nephrotic syndrome: a prospective observational study in Shanghai. World J Pediatr 10:59\u201363. https:\/\/doi.org\/10.1007\/s12519-014-0453-5","journal-title":"World J Pediatr"},{"key":"7180_CR50","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000013157","volume":"97","author":"YH Ahn","year":"2018","unstructured":"Ahn YH, Kim SH, Han KH, Choi HJ, Cho H, Lee JW, Shin JI, Cho MH, Lee JH, Park YS, Ha I-S, Cheong HI, Kim SY, Lee SJ, Kang HG (2018) Efficacy and safety of rituximab in childhood-onset, difficult-to-treat nephrotic syndrome: a multicenter open-label trial in Korea. Medicine 97:e13157. https:\/\/doi.org\/10.1097\/MD.0000000000013157","journal-title":"Medicine"},{"key":"7180_CR51","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1001\/jamapediatrics.2018.1323","volume":"172","author":"B Basu","year":"2018","unstructured":"Basu B, Sander A, Roy B, Preussler S, Barua S, Mahapatra TKS, Schaefer F (2018) Efficacy of Rituximab vs tacrolimus in pediatric corticosteroid-dependent nephrotic syndrome: a randomized clinical trial. JAMA Pediatr 172:757\u2013764. https:\/\/doi.org\/10.1001\/jamapediatrics.2018.1323","journal-title":"JAMA Pediatr"},{"key":"7180_CR52","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s00467-018-4063-7","volume":"34","author":"T Takahashi","year":"2019","unstructured":"Takahashi T, Okamoto T, Sato Y, Yamazaki T, Hayashi A, Aoyagi H, Ueno M, Kobayashi N, Uetake K, Nakanishi M, Ariga T (2019) Periodically repeated rituximab administrations in children with refractory nephrotic syndrome: 2-year multicenter observational study. Pediatr Nephrol 34:87\u201396. https:\/\/doi.org\/10.1007\/s00467-018-4063-7","journal-title":"Pediatr Nephrol"},{"key":"7180_CR53","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1007\/s00467-020-04570-y","volume":"35","author":"JA Kari","year":"2020","unstructured":"Kari JA, Alhasan KA, Albanna AS, Safdar OY, Shalaby MA, B\u00f6ckenhauer D, El-Desoky SM (2020) Rituximab versus cyclophosphamide as first steroid-sparing agent in childhood frequently relapsing and steroid-dependent nephrotic syndrome. Pediatr Nephrol 35:1445\u20131453. https:\/\/doi.org\/10.1007\/s00467-020-04570-y","journal-title":"Pediatr Nephrol"},{"key":"7180_CR54","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1007\/s00467-020-04540-4","volume":"35","author":"P Ravani","year":"2020","unstructured":"Ravani P, Lugani F, Pisani I, Bodria M, Piaggio G, Bartolomeo D, Prunotto M, Ghiggeri GM (2020) Rituximab for very low dose steroid-dependent nephrotic syndrome in children: a randomized controlled study. Pediatr Nephrol 35:1437\u20131444. https:\/\/doi.org\/10.1007\/s00467-020-04540-4","journal-title":"Pediatr Nephrol"},{"key":"7180_CR55","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1007\/s00467-020-04481-y","volume":"35","author":"P Ravani","year":"2020","unstructured":"Ravani P, Pisani I, Bodria M, Caridi G, Degl\u2019Innocenti ML, Ghiggeri GM (2020) Low-dose ofatumumab for multidrug-resistant nephrotic syndrome in children: a randomized placebo-controlled trial. Pediatr Nephrol 35:997\u20131003. https:\/\/doi.org\/10.1007\/s00467-020-04481-y","journal-title":"Pediatr Nephrol"},{"key":"7180_CR56","doi-asserted-by":"publisher","first-page":"2652","DOI":"10.1681\/ASN.2021040561","volume":"32","author":"P Ravani","year":"2021","unstructured":"Ravani P, Colucci M, Bruschi M, Vivarelli M, Cioni M, DiDonato A, Cravedi P, Lugani F, Antonini F, Prunotto M, Emma F, Angeletti A, Ghiggeri GM (2021) Human or chimeric monoclonal anti-CD20 antibodies for children with nephrotic syndrome: a superiority randomized trial. J Am Soc Nephrol 32:2652\u20132663. https:\/\/doi.org\/10.1681\/ASN.2021040561","journal-title":"J Am Soc Nephrol"},{"key":"7180_CR57","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1001\/jamapediatrics.2020.6150","volume":"175","author":"P Ravani","year":"2021","unstructured":"Ravani P, Lugani F, Drovandi S, Caridi G, Angeletti A, Ghiggeri GM (2021) Rituximab vs low-dose mycophenolate mofetil in recurrence of steroid-dependent nephrotic syndrome in children and young adults: a randomized clinical trial. JAMA Pediatr 175:631\u2013632. https:\/\/doi.org\/10.1001\/jamapediatrics.2020.6150","journal-title":"JAMA Pediatr"},{"key":"7180_CR58","doi-asserted-by":"publisher","first-page":"760","DOI":"10.15537\/smj.2022.43.7.20210727","volume":"43","author":"AA Al Salloum","year":"2022","unstructured":"Al Salloum AA, Al Herbish AJ, Al Hissi MA, Abdalla MS, Salim SB, Farhat AH, Shagal RA, Othman A, Alshaiban A, Temsah M-HA, Al-Eyadhy AA, Alhasan KA (2022) The outcome of rituximab in treating steroid dependent nephrotic syndrome.: histopathology and immunosuppressive drugs as predicting factors. Saudi Med J 43:760\u2013764. https:\/\/doi.org\/10.15537\/smj.2022.43.7.20210727","journal-title":"Saudi Med J"},{"key":"7180_CR59","doi-asserted-by":"publisher","first-page":"3117","DOI":"10.1007\/s00467-022-05475-8","volume":"37","author":"G Mathew","year":"2022","unstructured":"Mathew G, Sinha A, Ahmed A, Grewal N, Khandelwal P, Hari P, Bagga A (2022) Efficacy of rituximab versus tacrolimus in difficult-to-treat steroid-sensitive nephrotic syndrome: an open-label pilot randomized controlled trial. Pediatr Nephrol 37:3117\u20133126. https:\/\/doi.org\/10.1007\/s00467-022-05475-8","journal-title":"Pediatr Nephrol"},{"key":"7180_CR60","doi-asserted-by":"publisher","first-page":"275","DOI":"10.5114\/aoms\/145587","volume":"18","author":"L Wang","year":"2022","unstructured":"Wang L, Zhu J, Xia M, Hua R, Deng F (2022) Comparison of rituximab, cyclophosphamide, and tacrolimus as first steroid-sparing agents for complicated relapsing\/steroid-dependent nephrotic syndrome in children: an evaluation of the health-related quality of life. Arch Med Sci 18:275\u2013278. https:\/\/doi.org\/10.5114\/aoms\/145587","journal-title":"Arch Med Sci"},{"key":"7180_CR61","doi-asserted-by":"publisher","first-page":"1575","DOI":"10.1016\/j.ekir.2023.05.022","volume":"8","author":"B Basu","year":"2023","unstructured":"Basu B, Erdmann S, Sander A, Mahapatra TKS, Meis J, Schaefer F (2023) Long-term efficacy and safety of rituximab versus tacrolimus in children with steroid dependent nephrotic syndrome. Kidney Int Rep 8:1575\u20131584. https:\/\/doi.org\/10.1016\/j.ekir.2023.05.022","journal-title":"Kidney Int Rep"},{"key":"7180_CR62","doi-asserted-by":"publisher","first-page":"606","DOI":"10.7499\/j.issn.1008-8830.2301026","volume":"25","author":"Y Zhu","year":"2023","unstructured":"Zhu Y, Wu L, Wang Y, Zhu Y-F, Peng Y, Fang S-H, Zhang L-D, Deng F (2023) Efficacy and safety of low-dose rituximab in treatment of pediatric nephrotic syndrome: a prospective randomized controlled trial. Zhongguo dang dai er ke za zhi [Chinese J Contemp Pediatrics] 25:606\u2013611. https:\/\/doi.org\/10.7499\/j.issn.1008-8830.2301026","journal-title":"Zhongguo dang dai er ke za zhi [Chinese J Contemp Pediatrics]"},{"key":"7180_CR63","doi-asserted-by":"publisher","first-page":"3332","DOI":"10.1016\/j.ekir.2024.08.021","volume":"9","author":"P Cravedi","year":"2024","unstructured":"Cravedi P, Bigatti C, Kajana X, Verrina EE, Caridi G, Bruschi M, Ghiggeri GM, Angeletti A (2024) Efficacy and safety of subcutaneous rituximab in idiopathic nephrotic syndrome. Kidney Int Rep 9:3332\u20133334. https:\/\/doi.org\/10.1016\/j.ekir.2024.08.021","journal-title":"Kidney Int Rep"},{"key":"7180_CR64","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1016\/j.ekir.2024.02.1395","volume":"9","author":"J Liu","year":"2024","unstructured":"Liu J, Deng F, Wang X, Liu C, Sun S, Zhang R, Zhang A, Jiang X, Yan W, Dou Y, Zhang Y, Xie L, Qian B, Shen Q, Xu H (2024) Early rituximab as an add-on therapy in children with the initial episode of nephrotic syndrome. Kidney Int Rep 9:1220\u20131227. https:\/\/doi.org\/10.1016\/j.ekir.2024.02.1395","journal-title":"Kidney Int Rep"},{"key":"7180_CR65","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s10157-023-02431-0>","volume":"28","author":"K Nozu","year":"2024","unstructured":"Nozu K, Sako M, Tanaka S, Kano Y, Ohwada Y, Morohashi T, Hamada R, Ohtsuka Y, Oka M, Kamei K, Inaba A, Ito S, Sakai T, Kaito H, Shima Y, Ishikura K, Nakamura H, Nakanishi K, Horinouchi T, Konishi A, Omori T, Iijima K (2024) Rituximab in combination with cyclosporine and steroid pulse therapy for childhood-onset multidrug-resistant nephrotic syndrome: a multicenter single-arm clinical trial (JSKDC11 trial). Clin Exp Nephrol 28:337\u2013348. https:\/\/doi.org\/10.1007\/s10157-023-02431-0","journal-title":"Clin Exp Nephrol"},{"key":"7180_CR66","doi-asserted-by":"publisher","DOI":"10.1080\/0886022X.2025.2499902","volume":"47","author":"A-Q Sheng","year":"2025","unstructured":"Sheng A-Q, Liu F, Li Q-Y, Dou Y-L, Zhang X-J, Zhao J-L, Huang L-F, He S-Y, Lu Z-H, Feng C-Y, Wang J-J, Shen H-J, Fu H-D, Yan W-L, Mao J-H (2025) The efficacy and safety of rituximab monotherapy in the new onset pediatric idiopathic nephrotic syndrome: a randomized controlled clinical trial. Ren Fail 47:2499902. https:\/\/doi.org\/10.1080\/0886022X.2025.2499902","journal-title":"Ren Fail"},{"key":"7180_CR67","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s00467-024-06619-8","volume":"40","author":"R Sinha","year":"2025","unstructured":"Sinha R, Pradhan S, Raut S, Banerjee S, Sarkar S, Akhtar S, Dasgupta D, Poddar S, Mandal M, Kamal VK, Chaudhury AR, Tse Y (2025) Single (375 mg\/m(2)) vs. double dose of rituximab along with mycophenolate mofetil for children with steroid-dependent\/frequently relapsing nephrotic syndrome: a multicentre open-label randomized controlled trial. Pediatr Nephrol 40:995\u20131004. https:\/\/doi.org\/10.1007\/s00467-024-06619-8","journal-title":"Pediatr Nephrol"},{"key":"7180_CR68","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1097\/TP.0b013e3181880b35","volume":"86","author":"H Billing","year":"2008","unstructured":"Billing H, Rieger S, Ovens J, S\u00fcsal C, Melk A, Waldherr R, Opelz G, T\u00f6nshoff B (2008) Successful treatment of chronic antibody-mediated rejection with IVIG and rituximab in pediatric renal transplant recipients. Transplantation 86:1214\u20131221. https:\/\/doi.org\/10.1097\/TP.0b013e3181880b35","journal-title":"Transplantation"},{"key":"7180_CR69","doi-asserted-by":"publisher","first-page":"2607","DOI":"10.1111\/j.1600-6143.2008.02411.x","volume":"8","author":"V Zarkhin","year":"2008","unstructured":"Zarkhin V, Li L, Kambham N, Sigdel T, Salvatierra O, Sarwal MM (2008) A randomized, prospective trial of rituximab for acute rejection in pediatric renal transplantation. Am J Transplant 8:2607\u20132617. https:\/\/doi.org\/10.1111\/j.1600-6143.2008.02411.x","journal-title":"Am J Transplant"},{"key":"7180_CR70","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1111\/j.1432-2277.2012.01544.x","volume":"25","author":"H Billing","year":"2012","unstructured":"Billing H, Rieger S, S\u00fcsal C, Waldherr R, Opelz G, W\u00fchl E, T\u00f6nshoff B (2012) IVIG and rituximab for treatment of chronic antibody-mediated rejection: a prospective study in paediatric renal transplantation with a 2-year follow-up. Transpl Int 25:1165\u20131173. https:\/\/doi.org\/10.1111\/j.1432-2277.2012.01544.x","journal-title":"Transpl Int"},{"key":"7180_CR71","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1093\/rheumatology\/ker290","volume":"51","author":"AV Hadjinicolaou","year":"2012","unstructured":"Hadjinicolaou AV, Nisar MK, Parfrey H, Chilvers ER, Ostor AJ (2012) Non-infectious pulmonary toxicity of rituximab: a systematic review. Rheumatology (Oxford) 51:653\u2013662. https:\/\/doi.org\/10.1093\/rheumatology\/ker290","journal-title":"Rheumatology (Oxford)"},{"key":"7180_CR72","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/S0140-6736(22)01052-2","volume":"400","author":"M Wijsenbeek","year":"2022","unstructured":"Wijsenbeek M, Suzuki A, Maher TM (2022) Interstitial lung diseases. Lancet 400:769\u2013786. https:\/\/doi.org\/10.1016\/S0140-6736(22)01052-2","journal-title":"Lancet"},{"key":"7180_CR73","doi-asserted-by":"publisher","first-page":"528","DOI":"10.25259\/IJN_576_20","volume":"34","author":"SK Pradhan","year":"2024","unstructured":"Pradhan SK, Nayak S (2024) Rituximab induced rare cystic lesion in lungs in a nephrotic child: a case report. Indian J Nephrol 34:528\u2013532. https:\/\/doi.org\/10.25259\/IJN_576_20","journal-title":"Indian J Nephrol"},{"key":"7180_CR74","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s00467-022-05550-0","volume":"38","author":"G Mathew","year":"2023","unstructured":"Mathew G, George AS, Deepthi RV, Rose W, Verghese VP, Varghese R, Veeraraghavan B, Agarwal I (2023) Epidemiology and outcomes of pneumococcal sepsis in children with nephrotic syndrome in a developing country. Pediatr Nephrol 38:131\u2013137. https:\/\/doi.org\/10.1007\/s00467-022-05550-0","journal-title":"Pediatr Nephrol"},{"key":"7180_CR75","doi-asserted-by":"publisher","first-page":"2337","DOI":"10.1016\/j.ekir.2024.04.043","volume":"9","author":"L Schweitzer","year":"2024","unstructured":"Schweitzer L, Miko BA, Pereira MR (2024) Infectious disease prophylaxis during and after immunosuppressive therapy. Kidney Int Rep 9:2337\u20132352. https:\/\/doi.org\/10.1016\/j.ekir.2024.04.043","journal-title":"Kidney Int Rep"},{"key":"7180_CR76","doi-asserted-by":"publisher","unstructured":"Chan EYH, Wong SW, Lai FFY, Ho TW, Tong PC, Lai WM, Ma ALT, Yap DYH (2023) Long-term outcomes with rituximab as add-on therapy in severe childhood-onset lupus nephritis. Pediatr Nephrol 38:4001\u20134011. https:\/\/doi.org\/10.1007\/s00467-023-06025-6","DOI":"10.1007\/s00467-023-06025-6"},{"key":"7180_CR77","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s40272-023-00609-3","volume":"26","author":"EY Chan","year":"2024","unstructured":"Chan EY, Lai FF, Ma AL, Chan TM (2024) Managing lupus nephritis in children and adolescents. Paediatr Drugs 26:145\u2013161. https:\/\/doi.org\/10.1007\/s40272-023-00609-3","journal-title":"Paediatr Drugs"},{"key":"7180_CR78","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1093\/ndt\/gfu258","volume":"30","author":"K Kamei","year":"2015","unstructured":"Kamei K, Takahashi M, Fuyama M, Saida K, Machida H, Sato M, Ogura M, Ito S (2015) Rituximab-associated agranulocytosis in children with refractory idiopathic nephrotic syndrome: case series and review of literature. Nephrol Dial Transplant 30:91\u201396. https:\/\/doi.org\/10.1093\/ndt\/gfu258","journal-title":"Nephrol Dial Transplant"},{"key":"7180_CR79","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1053\/j.seminhematol.2010.01.009","volume":"47","author":"K Dunleavy","year":"2010","unstructured":"Dunleavy K, Tay K, Wilson WH (2010) Rituximab-associated neutropenia. Semin Hematol 47:180\u2013186. https:\/\/doi.org\/10.1053\/j.seminhematol.2010.01.009","journal-title":"Semin Hematol"},{"key":"7180_CR80","doi-asserted-by":"publisher","first-page":"3129","DOI":"10.1007\/s00467-024-06371-z","volume":"39","author":"EY-h Chan","year":"2024","unstructured":"Chan EY-h (2024) Rituximab-induced hypogammaglobulinemia in nephrotic syndrome: what is the true burden? Pediatr Nephrol 39:3129\u20133129. https:\/\/doi.org\/10.1007\/s00467-024-06371-z","journal-title":"Pediatr Nephrol"},{"key":"7180_CR81","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01653","volume":"10","author":"M Colucci","year":"2019","unstructured":"Colucci M, Carsetti R, Serafinelli J, Rocca S, Massella L, Gargiulo A, Lo Russo A, Capponi C, Cotugno N, Porzio O, Onetti Muda A, Palma P, Emma F, Vivarelli M (2019) Prolonged impairment of immunological memory after anti-CD20 treatment in pediatric idiopathic nephrotic syndrome. Front Immunol 10:1653. https:\/\/doi.org\/10.3389\/fimmu.2019.01653","journal-title":"Front Immunol"},{"key":"7180_CR82","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s00467-001-0817-7","volume":"17","author":"MJ Kemper","year":"2002","unstructured":"Kemper MJ, Altrogge H, Ganschow R, Muller-Wiefel DE (2002) Serum levels of immunoglobulins and IgG subclasses in steroid sensitive nephrotic syndrome. Pediatr Nephrol 17:413\u2013417. https:\/\/doi.org\/10.1007\/s00467-001-0817-7","journal-title":"Pediatr Nephrol"},{"key":"7180_CR83","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/0091-6749(78)90101-x","volume":"62","author":"GA Settipane","year":"1978","unstructured":"Settipane GA, Pudupakkam RK, McGowan JH (1978) Corticosteroid effect on immunoglobulins. J Allergy Clin Immunol 62:162\u2013166. https:\/\/doi.org\/10.1016\/0091-6749(78)90101-x","journal-title":"J Allergy Clin Immunol"},{"key":"7180_CR84","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1007\/s00467-019-04398-1","volume":"35","author":"C Parmentier","year":"2020","unstructured":"Parmentier C, Delbet J-D, Decramer S, Boyer O, Hogan J, Ulinski T (2020) Immunoglobulin serum levels in rituximab-treated patients with steroid-dependent nephrotic syndrome. Pediatr Nephrol 35:455\u2013462. https:\/\/doi.org\/10.1007\/s00467-019-04398-1","journal-title":"Pediatr Nephrol"},{"key":"7180_CR85","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2474-15-178","volume":"15","author":"H Marco","year":"2014","unstructured":"Marco H, Smith RM, Jones RB, Guerry M-J, Catapano F, Burns S, Chaudhry AN, Smith KG, Jayne DR (2014) The effect of rituximab therapy on immunoglobulin levels in patients with multisystem autoimmune disease. BMC Musculoskelet Disord 15:178. https:\/\/doi.org\/10.1186\/1471-2474-15-178","journal-title":"BMC Musculoskelet Disord"},{"key":"7180_CR86","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1007\/s00467-021-05304-4","volume":"37","author":"Y Inoki","year":"2022","unstructured":"Inoki Y, Kamei K, Nishi K, Sato M, Ogura M, Ishiguro A (2022) Incidence and risk factors of rituximab-associated hypogammaglobulinemia in patients with complicated nephrotic syndrome. Pediatr Nephrol 37:1057\u20131066. https:\/\/doi.org\/10.1007\/s00467-021-05304-4","journal-title":"Pediatr Nephrol"},{"key":"7180_CR87","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2020.102466","volume":"19","author":"K Kridin","year":"2020","unstructured":"Kridin K, Ahmed AR (2020) Post-rituximab immunoglobulin M (IgM) hypogammaglobulinemia. Autoimmun Rev 19:102466. https:\/\/doi.org\/10.1016\/j.autrev.2020.102466","journal-title":"Autoimmun Rev"},{"key":"7180_CR88","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1007\/s00467-020-04500-y","volume":"35","author":"M Shenoy","year":"2020","unstructured":"Shenoy M, Lennon R, Plant N, Wallace D, Kaur A (2020) Pre-emptive rituximab and plasma exchange does not prevent disease recurrence following living donor renal transplantation in high-risk idiopathic SRNS. Pediatr Nephrol 35:1081\u20131084. https:\/\/doi.org\/10.1007\/s00467-020-04500-y","journal-title":"Pediatr Nephrol"},{"key":"7180_CR89","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.kint.2019.09.033","volume":"97","author":"EY Chan","year":"2020","unstructured":"Chan EY, Webb H, Yu E, Ghiggeri GM, Kemper MJ, Ma AL, Yamamura T, Sinha A, Bagga A, Hogan J, Dossier C, Vivarelli M, Liu ID, Kamei K, Ishikura K, Saini P, Tullus K (2020) Both the rituximab dose and maintenance immunosuppression in steroid-dependent\/frequently-relapsing nephrotic syndrome have important effects on outcomes. Kidney Int 97:393\u2013401. https:\/\/doi.org\/10.1016\/j.kint.2019.09.033","journal-title":"Kidney Int"},{"key":"7180_CR90","doi-asserted-by":"publisher","first-page":"2356","DOI":"10.1016\/j.ekir.2023.08.014","volume":"8","author":"D Leung","year":"2023","unstructured":"Leung D, Chan EY-H, Mu X, Rosa Duque JS, Cheng SMS, Ho FT-W, Tong P-C, Lai W-M, Lee MHL, Chim S, Tam IYS, Tsang LCH, Kwan KKH, Chung Y, Wong HHW, Lee AMT, Li WY, Sze STK, Lam JHY, Lee DHL, Chan SM, Tu W, Peiris M, Ma AL-T, Lau YL (2023) Humoral and cellular immunogenicity of 3 doses of BNT162b2 in children with kidney diseases. Kidney Int Rep 8:2356\u20132367. https:\/\/doi.org\/10.1016\/j.ekir.2023.08.014","journal-title":"Kidney Int Rep"},{"key":"7180_CR91","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1016\/j.kint.2022.01.035","volume":"101","author":"AL Ma","year":"2022","unstructured":"Ma AL, Leung D, Chan EY, Chim S, Cheng S, Ho FT, Lai WM, Tong PC, Lee MH, Wong WH, Chan SM, Rosa Duque J, Peiris JSM, Lau YL (2022) Antibody responses to 2 doses of mRNA COVID-19 vaccine in pediatric patients with kidney diseases. Kidney Int 101:1069\u20131072. https:\/\/doi.org\/10.1016\/j.kint.2022.01.035","journal-title":"Kidney Int"},{"key":"7180_CR92","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1681\/ASN.2021050643","volume":"33","author":"K Iijima","year":"2022","unstructured":"Iijima K, Sako M, Oba M, Tanaka S, Hamada R, Sakai T, Ohwada Y, Ninchoji T, Yamamura T, Machida H, Shima Y, Tanaka R, Kaito H, Araki Y, Morohashi T, Kumagai N, Gotoh Y, Ikezumi Y, Kubota T, Kamei K, Fujita N, Ohtsuka Y, Okamoto T, Yamada T, Tanaka E, Shimizu M, Horinochi T, Konishi A, Omori T, Nakanishi K, Ishikura K, Ito S, Nakamura H, Nozu K, Japanese Study Group of Kidney Disease in Children (2022) Mycophenolate mofetil after rituximab for childhood-onset complicated frequently-relapsing or steroid-dependent nephrotic syndrome. J Am Soc Nephrol 33:401\u2013419. https:\/\/doi.org\/10.1681\/ASN.2021050643","journal-title":"J Am Soc Nephrol"},{"key":"7180_CR93","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1097\/BOR.0000000000000272","volume":"28","author":"R Kado","year":"2016","unstructured":"Kado R, Sanders G, McCune WJ (2016) Suppression of normal immune responses after treatment with rituximab. Curr Opin Rheumatol 28:251\u2013258. https:\/\/doi.org\/10.1097\/BOR.0000000000000272","journal-title":"Curr Opin Rheumatol"},{"key":"7180_CR94","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0037626","volume":"7","author":"N Venhoff","year":"2012","unstructured":"Venhoff N, Effelsberg NM, Salzer U, Warnatz K, Peter HH, Lebrecht D, Schlesier M, Voll RE, Thiel J (2012) Impact of rituximab on immunoglobulin concentrations and B cell numbers after cyclophosphamide treatment in patients with ANCA-associated vasculitides. PLoS One 7:e37626. https:\/\/doi.org\/10.1371\/journal.pone.0037626","journal-title":"PLoS ONE"},{"key":"7180_CR95","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s00467-017-3767-4","volume":"33","author":"J Hogan","year":"2018","unstructured":"Hogan J, Godron A, Baudouin V, Kwon T, Harambat J, Deschenes G, Niel O (2018) Combination therapy of rituximab and mycophenolate mofetil in childhood lupus nephritis. Pediatr Nephrol 33:111\u2013116. https:\/\/doi.org\/10.1007\/s00467-017-3767-4","journal-title":"Pediatr Nephrol"},{"issue":"Suppl 1","key":"7180_CR96","doi-asserted-by":"publisher","first-page":"i123","DOI":"10.1093\/ndt\/gfv076","volume":"30","author":"JG McGregor","year":"2015","unstructured":"McGregor JG, Hogan SL, Kotzen ES, Poulton CJ, Hu Y, Negrete-Lopez R, Kidd JM, Katsanos SL, Bunch DO, Nachman PH, Falk RJ (2015) Rituximab as an immunosuppressant in antineutrophil cytoplasmic antibody-associated vasculitis. Nephrol Dial Transplant 30(Suppl 1):i123-131. https:\/\/doi.org\/10.1093\/ndt\/gfv076","journal-title":"Nephrol Dial Transplant"},{"key":"7180_CR97","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/j.1600-6143.2009.02785.x","volume":"10","author":"N Kamar","year":"2010","unstructured":"Kamar N, Milioto O, Puissant-Lubrano B, Esposito L, Pierre MC, Mohamed AO, Lavayssiere L, Cointault O, Ribes D, Cardeau I, Nogier MB, Durand D, Abbal M, Blancher A, Rostaing L (2010) Incidence and predictive factors for infectious disease after rituximab therapy in kidney-transplant patients. Am J Transplant 10:89\u201398. https:\/\/doi.org\/10.1111\/j.1600-6143.2009.02785.x","journal-title":"Am J Transplant"},{"key":"7180_CR98","doi-asserted-by":"publisher","first-page":"172","DOI":"10.6002\/ect.2014.0156","volume":"14","author":"K Gulleroglu","year":"2016","unstructured":"Gulleroglu K, Baskin E, Moray G, Ozdemir H, Arslan H, Haberal M (2016) Rituximab therapy and infection risk in pediatric renal transplant patients. Exp Clin Transplant 14:172\u2013175. https:\/\/doi.org\/10.6002\/ect.2014.0156","journal-title":"Exp Clin Transplant"},{"key":"7180_CR99","doi-asserted-by":"publisher","unstructured":"Furer V, Rondaan C, Heijstek MW, Agmon-Levin N, Assen Sv, Bijl M, Breedveld FC, D'Amelio R, Dougados M, Kapetanovic MC, Laar JMv, Thurah Ad, Landew\u00e9 RB, Molto A, M\u00fcller-Ladner U, Schreiber K, Smolar L, Walker J, Warnatz K, Wulffraat NM, Elkayam O (2020) 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 79:39\u201352.  https:\/\/doi.org\/10.1136\/annrheumdis-2019-215882","DOI":"10.1136\/annrheumdis-2019-215882"},{"key":"7180_CR100","doi-asserted-by":"publisher","first-page":"e44","DOI":"10.1093\/cid\/cit684","volume":"58","author":"LG Rubin","year":"2014","unstructured":"Rubin LG, Levin MJ, Ljungman P, Davies EG, Avery R, Tomblyn M, Bousvaros A, Dhanireddy S, Sung L, Keyserling H, Kang I (2014) 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis 58:e44\u2013e100. https:\/\/doi.org\/10.1093\/cid\/cit684","journal-title":"Clin Infect Dis"},{"key":"7180_CR101","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.3390\/v14081780","volume":"14","author":"JM Araujo-Neto","year":"2022","unstructured":"Araujo-Neto JM, Guimaraes GS, Fernandes FF, Soares MA (2022) Hepatitis B surface antibody (Anti-HBs) kinetics during rituximab chemotherapy and performance of hepatitis B vaccine before immunosuppression: two prospective studies. Viruses 14:1780. https:\/\/doi.org\/10.3390\/v14081780","journal-title":"Viruses"},{"key":"7180_CR102","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000210281","volume":"104","author":"R Carvajal","year":"2025","unstructured":"Carvajal R, Guananga-Alvarez D, Tur C, Esperalba J, Rodriguez-Barranco M, Rando-Segura A, Borras-Bermejo B, Cobo-Calvo A, Carbonell-Mirabent P, Zules-Ona R, Rodrigo-Pendas JA, Martinez-Gomez X, Montalban X, Tintore M, Otero-Romero S (2025) Effect of the number of vaccine doses before starting anti-CD20 therapy on seroprotection rates against hepatitis B virus in people with MS. Neurology 104:e210281. https:\/\/doi.org\/10.1212\/WNL.0000000000210281","journal-title":"Neurology"},{"key":"7180_CR103","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1007\/s10875-012-9813-x","volume":"33","author":"RA Eisenberg","year":"2013","unstructured":"Eisenberg RA, Jawad AF, Boyer J, Maurer K, McDonald K, Prak ETL, Sullivan KE (2013) Rituximab-treated patients have a poor response to influenza vaccination. J Clin Immunol 33:388\u2013396. https:\/\/doi.org\/10.1007\/s10875-012-9813-x","journal-title":"J Clin Immunol"},{"key":"7180_CR104","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1136\/annrheumdis-2021-220781","volume":"80","author":"D Mrak","year":"2021","unstructured":"Mrak D, Tobudic S, Koblischke M, Graninger M, Radner H, Sieghart D, Hofer P, Perkmann T, Haslacher H, Thalhammer R, Winkler S, Bl\u00fcml S, Stiasny K, Aberle JH, Smolen JS, Heinz LX, Aletaha D, Bonelli M (2021) SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity. Ann Rheum Dis 80:1345\u20131350. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220781","journal-title":"Ann Rheum Dis"},{"key":"7180_CR105","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1002\/art.42060","volume":"74","author":"A-L Stefanski","year":"2022","unstructured":"Stefanski A-L, Rincon-Arevalo H, Schrezenmeier E, Karberg K, Szelinski F, Ritter J, Jahrsd\u00f6rfer B, Schrezenmeier H, Ludwig C, Sattler A, Kotsch K, Chen Y, Clau\u00dfnitzer A, Haibel H, Proft F, Guerra G, Durek P, Heinrich F, Ferreira-Gomes M, Burmester GR, Radbruch A, Mashreghi M-F, Lino AC, D\u00f6rner T (2022) B cell numbers predict humoral and cellular response upon SARS-CoV-2 vaccination among patients treated with rituximab. Arthritis Rheum 74:934\u2013947. https:\/\/doi.org\/10.1002\/art.42060","journal-title":"Arthritis Rheum"},{"key":"7180_CR106","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11121864","volume":"11","author":"L Lu","year":"2023","unstructured":"Lu L, Chan CY, Lim YY, Than M, Teo S, Lau PYW, Ng KH, Yap HK (2023) SARS-CoV-2 humoral immunity persists following rituximab therapy. Vaccines 11:1864. https:\/\/doi.org\/10.3390\/vaccines11121864","journal-title":"Vaccines"},{"key":"7180_CR107","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.711637","volume":"12","author":"G Blanchard-Rohner","year":"2021","unstructured":"Blanchard-Rohner G (2021) Vaccination in children with autoimmune disorders and treated with various immunosuppressive regimens: a comprehensive review and practical guide. Front Immunol 12:711637. https:\/\/doi.org\/10.3389\/fimmu.2021.711637","journal-title":"Front Immunol"},{"issue":"Suppl 1","key":"7180_CR108","doi-asserted-by":"publisher","first-page":"A15","DOI":"10.1016\/j.vaccine.2020.11.037","volume":"39","author":"F Caldera","year":"2021","unstructured":"Caldera F, Mercer M, Samson SI, Pitt JM, Hayney MS (2021) Influenza vaccination in immunocompromised populations: strategies to improve immunogenicity. Vaccine 39(Suppl 1):A15\u2013A23. https:\/\/doi.org\/10.1016\/j.vaccine.2020.11.037","journal-title":"Vaccine"},{"key":"7180_CR109","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s12882-022-02792-w","volume":"23","author":"RM Smith","year":"2022","unstructured":"Smith RM, Cooper DJ, Doffinger R, Stacey H, Al-Mohammad A, Goodfellow I, Baker S, Lear S, Hosmilo M, Pritchard N, Torpey N, Jayne D, Yiu V, Chalisey A, Lee J, Vilnar E, Cheung CK, Jones RB (2022) SARS-COV-2 vaccine responses in renal patient populations. BMC Nephrol 23:199. https:\/\/doi.org\/10.1186\/s12882-022-02792-w","journal-title":"BMC Nephrol"},{"key":"7180_CR110","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.1182\/bloodadvances.2021004629","volume":"5","author":"A Vijenthira","year":"2021","unstructured":"Vijenthira A, Gong I, Betschel SD, Cheung M, Hicks LK (2021) Vaccine response following anti-CD20 therapy: a systematic review and meta-analysis of 905 patients. Blood Adv 5:2624\u20132643. https:\/\/doi.org\/10.1182\/bloodadvances.2021004629","journal-title":"Blood Adv"},{"key":"7180_CR111","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1177\/1203475418811335","volume":"23","author":"KA Papp","year":"2019","unstructured":"Papp KA, Haraoui B, Kumar D, Marshall JK, Bissonnette R, Bitton A, Bressler B, Gooderham M, Ho V, Jamal S, Pope JE, Steinhart AH, Vinh DC, Wade J (2019) Vaccination guidelines for patients with immune-mediated disorders on immunosuppressive therapies. J Cutan Med Surg 23:50\u201374. https:\/\/doi.org\/10.1177\/1203475418811335","journal-title":"J Cutan Med Surg"},{"key":"7180_CR112","doi-asserted-by":"publisher","first-page":"3889","DOI":"10.1007\/s00467-023-05969-z","volume":"38","author":"K Kamei","year":"2023","unstructured":"Kamei K (2023) Live attenuated vaccines in patients receiving immunosuppressive agents. Pediatr Nephrol 38:3889\u20133900. https:\/\/doi.org\/10.1007\/s00467-023-05969-z","journal-title":"Pediatr Nephrol"},{"key":"7180_CR113","unstructured":"Government of Canada (2024) Hepatitis B vaccines: Canadian Immunization Guide. https:\/\/www.canada.ca\/en\/public-health\/services\/publications\/healthy-living\/canadian-immunization-guide-part-4-active-vaccines\/page-7-hepatitis-b-vaccine.html. Accessed 13 August 2025"},{"key":"7180_CR114","first-page":"300","volume":"64","author":"E Petrosky","year":"2015","unstructured":"Petrosky E, Bocchini JA, Hariri S, Chesson H, Curtis CR, Saraiya M, Unger ER, Markowitz LE, Centers for Disease Control and Prevention (CDC) (2015) Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep 64:300\u2013304","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"7180_CR115","doi-asserted-by":"publisher","first-page":"819","DOI":"10.15585\/mmwr.mm7337e2","volume":"73","author":"L Panagiotakopoulos","year":"2024","unstructured":"Panagiotakopoulos L, Moulia DL, Godfrey M, Link-Gelles R, Roper L, Havers FP, Taylor CA, Stokley S, Talbot HK, Schechter R, Brooks O, Daley MF, Fleming-Dutra KE, Wallace M (2024) Use of COVID-19 vaccines for persons aged \u22656 months: recommendations of the Advisory Committee on Immunization Practices - United States, 2024-2025. MMWR Morb Mortal Wkly Rep 73:819\u2013824. https:\/\/doi.org\/10.15585\/mmwr.mm7337e2","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"7180_CR116","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1007\/s00467-024-06565-5","volume":"40","author":"KA Alhasan","year":"2025","unstructured":"Alhasan KA, Raina R, Boyer O, Koh J, Bonilla-Felix M, Sethi SK, Amer YS, Coccia P, Temsah MH, Exantus J, Khan SA, Zhong X, Koch V, Duzova A, Vasudevan A, McCulloch M, Allen U, Filler G, Montini G, International Pediatric Nephrology Association (2025) IPNA clinical practice recommendations on care of pediatric patients with pre-existing kidney disease during seasonal outbreak of COVID-19. Pediatr Nephrol 40:1795\u20131815. https:\/\/doi.org\/10.1007\/s00467-024-06565-5","journal-title":"Pediatr Nephrol"},{"key":"7180_CR117","unstructured":"Committee on Infectious Diseases, American Academy of Pediatrics (2024) Red Book: 2024\u20132027 report of the Committee on Infectious Diseases. American Academy of Pediatrics, Itasca, Illinois"},{"key":"7180_CR118","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.jaut.2014.11.004","volume":"57","author":"DM Roberts","year":"2015","unstructured":"Roberts DM, Jones RB, Smith RM, Alberici F, Kumaratne DS, Burns S, Jayne DRW (2015) Immunoglobulin G replacement for the treatment of infective complications of rituximab-associated hypogammaglobulinemia in autoimmune disease: a case series. J Autoimmun 57:24\u201329. https:\/\/doi.org\/10.1016\/j.jaut.2014.11.004","journal-title":"J Autoimmun"},{"key":"7180_CR119","doi-asserted-by":"publisher","first-page":"1528414","DOI":"10.3389\/fimmu.2025.1528414","volume":"16","author":"J Cowan","year":"2025","unstructured":"Cowan J, Na I-K, Gladiator A, Kamieniak M, Mustafa SS (2025) Patient-reported outcomes with subcutaneous immunoglobulin in secondary immunodeficiency. Front Immunol 16:1528414. https:\/\/doi.org\/10.3389\/fimmu.2025.1528414","journal-title":"Front Immunol"},{"key":"7180_CR120","doi-asserted-by":"publisher","first-page":"1239014","DOI":"10.3389\/fped.2023.1239014","volume":"11","author":"EC Dinleyici","year":"2023","unstructured":"Dinleyici EC, Frey G, Kola E, Wippermann U, Bauhofer A, Staus A, Griffiths P, Azhharry M, Rohsiswatmo R (2023) Clinical efficacy of IgM-enriched immunoglobulin as adjunctive therapy in neonatal and pediatric sepsis: a systematic review and meta-analysis. Front Pediatr 11:1239014. https:\/\/doi.org\/10.3389\/fped.2023.1239014","journal-title":"Front Pediatr"},{"key":"7180_CR121","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1002\/art.41773","volume":"73","author":"SA Chung","year":"2021","unstructured":"Chung SA, Langford CA, Maz M, Abril A, Gorelik M, Guyatt G, Archer AM, Conn DL, Full KA, Grayson PC, Ibarra MF, Imundo LF, Kim S, Merkel PA, Rhee RL, Seo P, Stone JH, Sule S, Sundel RP, Vitobaldi OI, Warner A, Byram K, Dua AB, Husainat N, James KE, Kalot MA, Lin YC, Springer JM, Turgunbaev M, Villa-Forte A, Turner AS, Mustafa RA (2021) 2021 American College of Rheumatology\/Vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheumatol 73:1366\u20131383. https:\/\/doi.org\/10.1002\/art.41773","journal-title":"Arthritis Rheumatol"},{"key":"7180_CR122","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1016\/j.jaci.2022.01.025","volume":"149","author":"IM Otani","year":"2022","unstructured":"Otani IM, Lehman HK, Jongco AM, Tsao LR, Azar AE, Tarrant TK, Engel E, Walter JE, Truong TQ, Khan DA, Ballow M, Cunningham-Rundles C, Lu H, Kwan M, Barmettler S (2022) Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: a work group report of the AAAAI primary immunodeficiency and altered immune response committees. J Allergy Clin Immunol 149:1525\u20131560. https:\/\/doi.org\/10.1016\/j.jaci.2022.01.025","journal-title":"J Allergy Clin Immunol"},{"key":"7180_CR123","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.anai.2024.12.003","volume":"134","author":"R Monahan","year":"2025","unstructured":"Monahan R, Otani IM, Lehman HK, Mustafa SS (2025) A second look at secondary hypogammaglobulinemia. Ann Allergy Asthma Immunol 134:269\u2013278. https:\/\/doi.org\/10.1016\/j.anai.2024.12.003","journal-title":"Ann Allergy Asthma Immunol"},{"key":"7180_CR124","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1111\/trf.18083","volume":"65","author":"J Cote","year":"2025","unstructured":"Cote J, Chaloult-Lavoie M, Poulin E, Hayes LA, Singbo MNU, Ouellet P, Pelland-Marcotte MC (2025) Incidence of adverse events related to intravenous immunoglobulin therapy in children. Transfusion 65:88\u201399. https:\/\/doi.org\/10.1111\/trf.18083","journal-title":"Transfusion"},{"key":"7180_CR125","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1093\/ajhp\/zxac139","volume":"79","author":"RH Kobayashi","year":"2022","unstructured":"Kobayashi RH, Rigas MT (2022) Immune globulin therapy and kidney disease: overview and screening, monitoring, and management recommendations. Am J Health Syst Pharm 79:1415\u20131423. https:\/\/doi.org\/10.1093\/ajhp\/zxac139","journal-title":"Am J Health Syst Pharm"},{"key":"7180_CR126","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1136\/ard-2022-223335","volume":"82","author":"GE Fragoulis","year":"2023","unstructured":"Fragoulis GE, Nikiphorou E, Dey M, Zhao SS, Courvoisier DS, Arnaud L, Atzeni F, Behrens GM, Bijlsma JW, B\u00f6hm P, Constantinou CA, Garcia-Diaz S, Kapetanovic MC, Lauper K, Lu\u00eds M, Morel J, Nagy G, Polverino E, van Rompay J, Sebastiani M, Strangfeld A, de Thurah A, Galloway J, Hyrich KL (2023) 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 82:742\u2013753. https:\/\/doi.org\/10.1136\/ard-2022-223335","journal-title":"Ann Rheum Dis"},{"key":"7180_CR127","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1097\/TP.0000000000005374","volume":"109","author":"CN Kotton","year":"2025","unstructured":"Kotton CN, Kumar D, Manuel O, Chou S, Hayden RT, Danziger-Isakov L, Asberg A, Tedesco-Silva H, Humar A, Transplantation Society International CMV Consensus Group (2025) The fourth international consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 109:1066\u20131110. https:\/\/doi.org\/10.1097\/TP.0000000000005374","journal-title":"Transplantation"},{"key":"7180_CR128","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jfma.2024.05.009","volume":"124","author":"MC Chung","year":"2025","unstructured":"Chung MC, Chen CH, Chang SS, Lee CY, Tian YC, Wu MY, Wang HH, Yu CC, Chen TW, Kao CC, Hsu CY, Chiang YJ, Wu MJ, Chen YT, Wu MS (2025) Prevention and management of cytomegalovirus infection and disease in kidney transplant: a consensus statement of the Transplantation Society of Taiwan. J Formos Med Assoc 124:104\u2013111. https:\/\/doi.org\/10.1016\/j.jfma.2024.05.009","journal-title":"J Formos Med Assoc"},{"key":"7180_CR129","doi-asserted-by":"publisher","first-page":"6053","DOI":"10.3748\/wjg.v27.i36.6053","volume":"27","author":"M Stinco","year":"2021","unstructured":"Stinco M, Rubino C, Trapani S, Indolfi G (2021) Treatment of hepatitis B virus infection in children and adolescents. World J Gastroenterol 27:6053\u20136063. https:\/\/doi.org\/10.3748\/wjg.v27.i36.6053","journal-title":"World J Gastroenterol"},{"key":"7180_CR130","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2025-073622","volume":"156","author":"Committee on Infectious Diseases","year":"2025","unstructured":"Committee on Infectious Diseases (2025) Recommendations for prevention and control of influenza in children, 2025\u20132026: technical report. Pediatrics 156:e2025073622. https:\/\/doi.org\/10.1542\/peds.2025-073622","journal-title":"Pediatrics"},{"key":"7180_CR131","doi-asserted-by":"publisher","first-page":"4271","DOI":"10.1007\/s00431-023-05080-3","volume":"182","author":"D Clemente Garulo","year":"2023","unstructured":"Clemente Garulo D, Nunez-Cuadros E, Camacho Lovillo M, Calzada-Hernandez J, Guillen Martin S, Fernandez Silveira L, Lirola Cruz MJ, Tagarro A, Alcobendas Rueda RM, Lopez Lopez A, Satrustegi Aritziturri M, Calvo C (2023) Position statement on infection screening, prophylaxis, and vaccination in pediatric patients with rheumatic diseases and immunosuppressive therapies, part 2: infection prophylaxis. Eur J Pediatr 182:4271\u20134284. https:\/\/doi.org\/10.1007\/s00431-023-05080-3","journal-title":"Eur J Pediatr"},{"key":"7180_CR132","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6901a1","volume":"69","author":"TR Sterling","year":"2020","unstructured":"Sterling TR, Njie G, Zenner D, Cohn DL, Reves R, Ahmed A, Menzies D, Horsburgh CR, Crane CM, Burgos M, LoBue P, Winston CA, Belknap R (2020) Guidelines for the treatment of latent tuberculosis infection: recommendations from the National Tuberculosis Controllers Association and CDC, 2020. MMWR Recomm Rep 69:1\u201311. https:\/\/doi.org\/10.15585\/mmwr.rr6901a1","journal-title":"MMWR Recomm Rep"},{"key":"7180_CR133","doi-asserted-by":"publisher","DOI":"10.1016\/j.pmedr.2019.101016","volume":"16","author":"AM Lachiewicz","year":"2019","unstructured":"Lachiewicz AM, Srinivas ML (2019) Varicella-zoster virus post-exposure management and prophylaxis: a review. Prev Med Rep 16:101016. https:\/\/doi.org\/10.1016\/j.pmedr.2019.101016","journal-title":"Prev Med Rep"},{"key":"7180_CR134","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1002\/art.42541","volume":"75","author":"JW Park","year":"2023","unstructured":"Park JW, Curtis JR, Choi SR, Kim MJ, Ha YJ, Kang EH, Lee YJ, Lee EB (2023) Risk\u2013benefit analysis of primary prophylaxis against Pneumocystis jirovecii pneumonia in patients with rheumatic diseases receiving rituximab. Arthritis Rheum 75:2036\u20132044. https:\/\/doi.org\/10.1002\/art.42541","journal-title":"Arthritis Rheum"},{"key":"7180_CR135","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1177\/1060028016650107","volume":"50","author":"LJ Avino","year":"2016","unstructured":"Avino LJ, Naylor SM, Roecker AM (2016) Pneumocystis jirovecii pneumonia in the non-HIV-infected population. Ann Pharmacother 50:673\u2013679. https:\/\/doi.org\/10.1177\/1060028016650107","journal-title":"Ann Pharmacother"},{"key":"7180_CR136","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1056\/NEJM198706253162604","volume":"316","author":"WT Hughes","year":"1987","unstructured":"Hughes WT, Rivera GK, Schell MJ, Thornton D, Lott L (1987) Successful intermittent chemoprophylaxis for Pneumocystis carinii pneumonitis. N Engl J Med 316:1627\u20131632. https:\/\/doi.org\/10.1056\/NEJM198706253162604","journal-title":"N Engl J Med"},{"key":"7180_CR137","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.ijid.2022.10.004","volume":"125","author":"RY Chen","year":"2022","unstructured":"Chen RY, Li DW, Wang JY, Zhuang SY, Wu HY, Wu JJ, Qu JW, Sun N, Zhong C, Zhu C, Zhang M, Yu YT, Yuan XD (2022) Prophylactic effect of low-dose trimethoprim-sulfamethoxazole for Pneumocystis jirovecii pneumonia in adult recipients of kidney transplantation: a real-world data study. Int J Infect Dis 125:209\u2013215. https:\/\/doi.org\/10.1016\/j.ijid.2022.10.004","journal-title":"Int J Infect Dis"},{"key":"7180_CR138","doi-asserted-by":"publisher","first-page":"123","DOI":"10.5863\/1551-6776-28.2.123","volume":"28","author":"JK Chen","year":"2023","unstructured":"Chen JK, Guerci J, Corbo H, Richmond M, Martinez M (2023) Low-dose TMP-SMX for Pneumocystis jirovecii pneumonia prophylaxis in pediatric solid organ transplant recipients. J Pediatr Pharmacol Ther 28:123\u2013128. https:\/\/doi.org\/10.5863\/1551-6776-28.2.123","journal-title":"J Pediatr Pharmacol Ther"},{"key":"7180_CR139","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/j.chest.2021.11.007","volume":"161","author":"JW Park","year":"2022","unstructured":"Park JW, Curtis JR, Jun KI, Kim TM, Heo DS, Ha J, Suh K-S, Lee K-W, Lee H, Yang J, Kim MJ, Choi Y, Lee EB (2022) Primary prophylaxis for Pneumocystis jirovecii pneumonia in patients receiving rituximab. Chest 161:1201\u20131210. https:\/\/doi.org\/10.1016\/j.chest.2021.11.007","journal-title":"Chest"},{"key":"7180_CR140","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.1136\/annrheumdis-2017-212861","volume":"77","author":"A Kronbichler","year":"2018","unstructured":"Kronbichler A, Kerschbaum J, Gopaluni S, Tieu J, Alberici F, Jones RB, Smith RM, Jayne DRW (2018) Trimethoprim-sulfamethoxazole prophylaxis prevents severe\/life-threatening infections following rituximab in antineutrophil cytoplasm antibody-associated vasculitis. Ann Rheum Dis 77:1440\u20131447. https:\/\/doi.org\/10.1136\/annrheumdis-2017-212861","journal-title":"Ann Rheum Dis"},{"key":"7180_CR141","doi-asserted-by":"publisher","first-page":"195","DOI":"10.5114\/ceh.2019.87631","volume":"5","author":"M Paw\u0142owska","year":"2019","unstructured":"Paw\u0142owska M, Flisiak R, Gil L, Horban A, Hus I, Jaroszewicz J, Lech-Mara\u0144da E, Styczy\u0144ski J (2019) Prophylaxis of hepatitis B virus (HBV) infection reactivation - recommendations of the Working Group for prevention of HBV reactivation. Clin Exp Hepatol 5:195\u2013202. https:\/\/doi.org\/10.5114\/ceh.2019.87631","journal-title":"Clin Exp Hepatol"},{"key":"7180_CR142","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1097\/MPG.0000000000002628","volume":"70","author":"G Indolfi","year":"2020","unstructured":"Indolfi G, Abdel-Hady M, Bansal S, Debray D, Smets F, Czubkowski P, van der Woerd W, Samyn M, Jahnel J, Gupte G, Zellos A, Mozer-Glassberg Y, Verkade HJ, Sokal E, Fischler B (2020) Management of hepatitis B virus infection and prevention of hepatitis B virus reactivation in children with acquired immunodeficiencies or undergoing immune suppressive, cytotoxic, or biological modifier therapies. J Pediatr Gastroenterol Nutr 70:527\u2013538. https:\/\/doi.org\/10.1097\/MPG.0000000000002628","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"7180_CR143","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1053\/j.gastro.2024.11.008","volume":"168","author":"FS Ali","year":"2025","unstructured":"Ali FS, Nguyen MH, Hernaez R, Huang DQ, Wilder J, Piscoya A, Simon TG, Falck-Ytter Y (2025) AGA clinical practice guideline on the prevention and treatment of hepatitis B virus reactivation in at-risk individuals. Gastroenterology 168:267\u2013284. https:\/\/doi.org\/10.1053\/j.gastro.2024.11.008","journal-title":"Gastroenterology"},{"key":"7180_CR144","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1002\/hep.29800","volume":"67","author":"NA Terrault","year":"2018","unstructured":"Terrault NA, Lok ASF, McMahon BJ, Chang K-M, Hwang JP, Jonas MM, Brown RS, Bzowej NH, Wong JB (2018) Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology (Baltimore, MD) 67:1560\u20131599. https:\/\/doi.org\/10.1002\/hep.29800","journal-title":"Hepatology (Baltimore, MD)"},{"key":"7180_CR145","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jmii.2011.12.020","volume":"46","author":"K-M Lin","year":"2013","unstructured":"Lin K-M, Lin J-C, Tseng W-Y, Cheng T-T (2013) Rituximab-induced hepatitis C virus reactivation in rheumatoid arthritis. J Microbiol Immunol Infect 46:65\u201367. https:\/\/doi.org\/10.1016\/j.jmii.2011.12.020","journal-title":"J Microbiol Immunol Infect"},{"key":"7180_CR146","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae353","volume":"11","author":"M Foca","year":"2024","unstructured":"Foca M, Demirhan S, Munoz FM, Valencia Deray KG, Bocchini CE, Sharma TS, Sherman G, Muller WJ, Heald-Sargent T, Danziger-Isakov L, Blum S, Boguniewicz J, Bacon S, Joseph T, Smith J, Ardura MI, Su Y, Maron GM, Ferrolino J, Herold BC (2024) Multicenter analysis of valganciclovir prophylaxis in pediatric solid organ transplant recipients. Open Forum Infect Dis 11:ofae353. https:\/\/doi.org\/10.1093\/ofid\/ofae353","journal-title":"Open Forum Infect Dis"},{"key":"7180_CR147","doi-asserted-by":"publisher","first-page":"e13652","DOI":"10.1111\/ctr.13652","volume":"33","author":"UD Allen","year":"2019","unstructured":"Allen UD, Preiksaitis JK, AST Infectious Diseases Community of Practice (2019) Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant 33:e13652. https:\/\/doi.org\/10.1111\/ctr.13652","journal-title":"Clin Transplant"},{"key":"7180_CR148","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1177\/0956462420946662","volume":"31","author":"G Alfano","year":"2020","unstructured":"Alfano G, Giaroni F, Fontana F, Neri L, Mosconi G, Mussini C, Guaraldi G, Cappelli G (2020) Rituximab in people living with HIV affected by immune-mediated renal diseases: a case-series. Int J STD AIDS 31:1426\u20131431. https:\/\/doi.org\/10.1177\/0956462420946662","journal-title":"Int J STD AIDS"},{"key":"7180_CR149","unstructured":"Sadiq U, Shrestha U, Guzman N (2023) Prevention of Opportunistic Infections in HIV\/AIDS. StatPearls Publishing, Treasure Island, Florida"},{"key":"7180_CR150","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1007\/s00508-022-02062-7","volume":"134","author":"E Rath","year":"2022","unstructured":"Rath E, Bonelli M, Duftner C, Gruber J, Mandl P, Moazedi-Furst F, Pieringer H, Puchner R, Flick H, Salzer HJF, Weiss G, Winkler S, Skvara H, Moschen A, Hofer H, Feurstein J, Sautner J (2022) National consensus statement by the Austrian Societies for Rheumatology, Pulmonology, Infectiology, Dermatology and Gastroenterology regarding the management of latent tuberculosis and the associated utilization of biologic and targeted synthetic disease modifying antirheumatic drugs (DMARDs). Wien Klin Wochenschr 134:751\u2013765. https:\/\/doi.org\/10.1007\/s00508-022-02062-7","journal-title":"Wien Klin Wochenschr"},{"key":"7180_CR151","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1142\/s2661341721500012","volume":"21","author":"CKY O\u2019Young","year":"2021","unstructured":"O\u2019Young CKY, Ho KM, So H, Mok TYW, Leung CC, Chau CH, Chan CK (2021) Recommendations on management of latent tuberculosis infection in patients initiating anti-tumor necrosis factor biologics. J Clin Rheumatol Immunol 21:51\u201357. https:\/\/doi.org\/10.1142\/s2661341721500012","journal-title":"J Clin Rheumatol Immunol"},{"key":"7180_CR152","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1093\/jpids\/pit030","volume":"2","author":"AT Cruz","year":"2013","unstructured":"Cruz AT, Ahmed A, Mandalakas AM, Starke JR (2013) Treatment of latent tuberculosis infection in children. J Pediatric Infect Dis 2:248\u2013258. https:\/\/doi.org\/10.1093\/jpids\/pit030","journal-title":"J Pediatric Infect Dis"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-026-07180-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-026-07180-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-026-07180-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T23:06:32Z","timestamp":1785452792000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-026-07180-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,23]]},"references-count":152,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["7180"],"URL":"https:\/\/doi.org\/10.1007\/s00467-026-07180-2","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,23]]},"assertion":[{"value":"27 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}